Eric Venker, President & Immunovant CEO at Roivant Sciences Ltd. (ROIV), sold 400,000 shares at $20.85 ($8.3M) on 2025-12-09, disclosed to the SEC on 2025-12-11.
Scheduled sale ($8.3M) by President & Immunovant CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.85 | 200,000 | $4.2M | 50.0% |
| 2 | $20.85 | 200,000 | $4.2M | 50.0% |
| Total | $20.85 avg | 400,000 | $8.3M | 100% |
| Filing → |
| ROIV | SELL | 2026-09-01 | $7.2M | — | Filing → |
| ROIV | SELL | 2026-07-29 | $7.0M | — | Filing → |
| IMVT | SELL | 2026-07-06 | $119K | — | Filing → |